Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis

Blood

Volumn 99, Issue 11, 2002, Pages 4166-4173

  Metelitsa, Leonid S ^a   Gillies, Stephen D ^a   Super, Michael ^a   Shimada, Hiroyuki ^a   Reynolds, C Patrick ^a   Seeger, Robert C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; CD11B ANTIGEN; CD32 ANTIGEN; FC RECEPTOR; GRANULOCYTE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DEGRANULATION; ELECTRON MICROSCOPY; EXOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0036625059     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.4166     Document Type: Article

References (41)

1. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA. Immunocytokines: A promising approach to cancer immunotherapy. Pharmacol Ther. 1998;80:277-292.
2. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A. 1994;91:9626-9630.
3. Pancook JD, Becker JC, Gillies SD, Reisfeld RA. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother. 1996;42:88-92.
4. Schrama D, Thor SP, Fischer WH, et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001;14:111-121.
5. Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood. 1992;79:1484-1490.
6. Ottonello L, Epstein AL, Dapino P, Barbera P, Morone P, Dallegri F. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: Intervention of FcγRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Blood. 1999;93:3505-3511.
7. Wurflein D, Dechant M, Stockmeyer B, et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res. 1998;58:3051-3058.
8. Heijnen IA, Rijks LJ, Schiel A, et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: Efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcγ receptor I bispecific antibodies. J Immunol. 1997;159:5629-5639.
9. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97:339-345.
10. Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL. The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res. 1999;5:4259-4263.
11. Schlff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte FcγRI expression and improved Fcγ receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. 1997;90:3187-3194.
12. Michon JM, Gey A, Moutel S, et al. In vivo induction of functional FcγRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br J Haematol. 1998;100:550-556.
13. van Spriel AB, Leusen JH, van Egmond M, et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood. 2001;97:2478-2486.
14. Gillies SD, Lan Y, Lo KM, Super M, Wesolowski J. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res. 1999;59:2159-2166.
15. Moulding DA, Hart CA, Edwards SW. Regulation of neutrophil FcγRIIIb (CD16) surface expression following delayed apoptosis in response to GM-CSF and sodium butyrate. J Leukoc Biol. 1999;65:875-882.
16. van Kessel KP, van Strijp JA, van der Tol ME, et al. Quantitation of conjugate formation between human polymorphonuclear leukocytes and antibody-coated target cells by flow cytometry: The role of Fc receptor and LFA-1 antigen. J Leukoc Biol. 1989;46:467-475.
17. Berton G, Yan SR, Fumagalli L, Lowell CA. Neutrophil activation by adhesion: Mechanisms and pathophysiological implications. Int J Clin Lab Res. 1996;26:160-177.
18. Jones SL, Knaus UG, Bokoch GM, Brown EJ. Two signaling mechanisms for activation of αM β2 avidity in polymorphonuclear neutrophils. J Biol Chem. 1998;273:10556-10566.
19. Seeger RC, Rayner SA, Banerjee A, et al. Morphology, growth chromosomal pattern, and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res. 1977;37:1364-1371.
20. Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem. 1993;4:230-235.
21. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst. 2000;92:1897-1909.
22. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996;87:4440-4447.
23. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry. 1996;24:204-213.
24. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother. 2000;48:603-612.
25. Reynolds CP, Biedler JL, Spengler BA. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst. 1986;76:375-387.
26. Todd RF III, Nadler LM, Schlossman SF. Antigens on human monocytes identified by monoclonal antibodies. J Immunol. 1981;126:1435-1442.
27. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261-267.
28. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3:19-24.
29. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric antidisialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-2180.
30. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study. J Clin Oncol. 2000;18:4077-4085.
31. Hogg N, Selvendran Y. An anti-human monocyte/macrophage monoclonal antibody, reacting most strongly with macrophages in lymphoid tissue. Cell Immunol. 1985;92:247-253.
32. Dransfield I, Hogg N. Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits. EMBO J. 1989;8:3759-3765.
33. Stewart M, Hogg N. Regulation of leukocyte integrin function: Affinity vs. avidity. J Cell Biochem. 1996;61:554-561.
34. Niessen HW, Verhoeven AJ. Differential up-regulation of specific and azurophilic granule membrane markers in electropermeabilized neutrophils. Cell Signal. 1992;4:501-509.
35. McDowall A, Leitinger B, Stanley P, Bates PA, Randi AM, Hogg N. The I domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1). J Biol Chem. 1998;273:27396-27403.
36. Hogg N, Stewart MP, Scarth SL, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional β2 integrins mac-1 and LFA-1 [In Process Citation]. J Clin Invest. 1999;103:97-106.
37. Wright SD, Silverstein SC. Phagocytosing macrophages exclude proteins from the zones of contact with opsonized targets. Nature. 1984;309:359-361.
38. Barker E, Reisfeld RA. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 1993;53:362-367.
39. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73:1936-1941.
40. Bouillon M, Tessier P, Boulianne R, Destrempe R, Audette M. Regulation by retinoic acid of ICAM-1 expression on human tumor cell lines. Biochim Biophys Acta. 1991;1097:95-102.
41. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells (see comments]. J Clin Invest. 1996;98:50-61.